Ganapathy Saravanan1, Ponnusamy Ponmurugan2. 1. Department of Biochemistry, Centre for Biological science, K.S.Rangasamy College of Arts and Science, Thokkavadi, Tiruchengode,Tamil Nadu, India. 2. Department of Biotechnology, K.S.Rangasamy College of Technology, Thokkavadi, Tiruchengode, Tamil Nadu, India.
Abstract
BACKGROUND: S-allylcysteine, a garlic derivative, could have a protective effect against pathogenesis of diabetes mellitus. OBJECTIVES: Sustained free radical generation and oxidative damage to system leads to the final conclusion phase of diabetes and also it coexists with a constant diminution in the antioxidant status.The present study aims to evaluate the therapeutic effects of S-allylcysteine (SAC) against adipocytes hormones and antioxidant defense systems of plasma and erythrocytes of treptozotocin (STZ) induced diabetes in rats. MATERIALS AND METHODS: Diabetic rats were administered SAC (150 mg/kg b.w) orally for 45 days. At 46(th) day, the rats were anesthetized, and blood and liver sample were collected for analyzing glucose, plasma insulin, CYP2E1 activity, Thiobarbituric acid reactive substances (TBARS), hydroperoxide, enzymatic and nonenzymatic antioxidants, reduced glutathione (GSH), ceruloplasmin, plasma leptin, and adiponectin. RESULTS: The levels of glucose, CYP2E1 activity, Thiobarbituric acid reactive substances (TBARS), hydroperoxide, and ceruloplasmin were increased significantly; whereas, the levels of plasma insulin, reduced glutathione, enzymatic and nonenzymatic antioxidants, leptin and adiponectin were decreased in experimental diabetic rats. Administration of SAC to diabetic rats led to a decrease in the levels of glucose, CYP2E1 activity, TBARS, and ceruloplasmin. In addition, the levels of plasma insulin, enzymatic and nonenzymatic antioxidants leptin and adiponectin were increased in SAC treated diabetic rats. Gliclazide, a standard drug for diabetes, was used for the comparative purpose. CONCLUSIONS: The results of the present investigation suggest that SAC could be used as a food supplement in the treatment of diabetes characterized by provoked antioxidant status, altered blood glucose, and hormones level.
BACKGROUND:S-allylcysteine, a garlic derivative, could have a protective effect against pathogenesis of diabetes mellitus. OBJECTIVES: Sustained free radical generation and oxidative damage to system leads to the final conclusion phase of diabetes and also it coexists with a constant diminution in the antioxidant status.The present study aims to evaluate the therapeutic effects of S-allylcysteine (SAC) against adipocytes hormones and antioxidant defense systems of plasma and erythrocytes of treptozotocin (STZ) induced diabetes in rats. MATERIALS AND METHODS:Diabeticrats were administered SAC (150 mg/kg b.w) orally for 45 days. At 46(th) day, the rats were anesthetized, and blood and liver sample were collected for analyzing glucose, plasma insulin, CYP2E1 activity, Thiobarbituric acid reactive substances (TBARS), hydroperoxide, enzymatic and nonenzymatic antioxidants, reduced glutathione (GSH), ceruloplasmin, plasma leptin, and adiponectin. RESULTS: The levels of glucose, CYP2E1 activity, Thiobarbituric acid reactive substances (TBARS), hydroperoxide, and ceruloplasmin were increased significantly; whereas, the levels of plasma insulin, reduced glutathione, enzymatic and nonenzymatic antioxidants, leptin and adiponectin were decreased in experimental diabeticrats. Administration of SAC to diabeticrats led to a decrease in the levels of glucose, CYP2E1 activity, TBARS, and ceruloplasmin. In addition, the levels of plasma insulin, enzymatic and nonenzymatic antioxidants leptin and adiponectin were increased in SAC treated diabeticrats. Gliclazide, a standard drug for diabetes, was used for the comparative purpose. CONCLUSIONS: The results of the present investigation suggest that SAC could be used as a food supplement in the treatment of diabetes characterized by provoked antioxidant status, altered blood glucose, and hormones level.
Authors: Peter M Thulé; Adam G Campbell; Dean J Kleinhenz; Darin E Olson; Joshua J Boutwell; Roy L Sutliff; C Michael Hart Journal: Am J Physiol Endocrinol Metab Date: 2005-08-23 Impact factor: 4.310
Authors: R L Atanasiu; D Stea; M A Mateescu; C Vergely; F Dalloz; F Briot; V Maupoil; R Nadeau; L Rochette Journal: Mol Cell Biochem Date: 1998-12 Impact factor: 3.396
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: Khaled K Al-Qattan; Martha Thomson; Divya Jayasree; Muslim Ali Journal: Evid Based Complement Alternat Med Date: 2016-05-18 Impact factor: 2.629